Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genomic Valley BiotechBOM:539206 +4.79%59 PS Ratio is 36.63 as of Aug. 17, 2026, which is 129% above its 10-year median of 16.03. GuruFocus rates BOM:539206 with a GF Score™ of 59/100 and a GF Value™ of ₹12.84 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 933 Biotechnology companies, Genomic Valley Biotech ranks worse than 75.56% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Genomic Valley Biotech's share price is ₹30.40.
Genomic Valley Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.83. Hence, Genomic Valley Biotech's PS Ratio for today is 36.63.
The historical rank and industry rank for Genomic Valley Biotech's PS Ratio or its related term are showing as below:
BOM:539206'
s PS Ratio Range Over the Past 10 Years
Min: 2.33 Med: 16.03 Max: 140.53
Current: 36.63
During the past 12 years, Genomic Valley Biotech's highest PS Ratio was 140.53. The lowest was 2.33. And the median was 16.03.
BOM:539206's PS Ratio is ranked worse than 75.56% of 933
companies
in the Biotechnology industry
Industry Median: 9.38
vs BOM:539206: 36.63
Genomic Valley Biotech Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Genomic Valley Biotech was -68.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -53.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 18.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 2.70% per year.
During the past 12 years, Genomic Valley Biotech's highest 3-Year average Revenue per Share Growth Rate was 160.90% per year. The lowest was -58.70% per year. And the median was 25.30% per year.
Genomic Valley Biotech (BOM:539206) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:539206 vs VRTX, REGN, RVMD: PS Ratio Comparison
For the Biotechnology subindustry, Genomic Valley Biotech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomic Valley Biotech PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genomic Valley Biotech's PS Ratio distribution charts can be found below:
* The bar in red indicates where Genomic Valley Biotech's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Genomic Valley Biotech's Share Price of today is ₹30.40. Genomic Valley Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.83.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Genomic Valley Biotech (BOM:539206) has a PS Ratio of 36.63 as of Aug. 17, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Genomic Valley Biotech and its competitors. This is 129% above median its historical median of 16.03. Over the past decade, Genomic Valley Biotech's PS Ratio has ranged from 2.33 to 140.53. According to the industry distribution chart, Genomic Valley Biotech ranks #705 out of 933 companies in the Biotechnology industry, placing it in the top 75.6%.
Is Genomic Valley Biotech's PS Ratio too high?
Genomic Valley Biotech's current PS Ratio of 36.63 is 129% above median its 10-year median of 16.03. Over the past 10 years, this metric has ranged from a low of 2.33 to a high of 140.53. The Biotechnology industry median PS Ratio is 9.38. Genomic Valley Biotech's value of 36.63 is 290.5% above this industry median. Based on the distribution chart, Genomic Valley Biotech ranks #705 out of 933 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genomic Valley Biotech has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genomic Valley Biotech's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genomic Valley Biotech ranks #705 out of 933 companies for PS Ratio. This places Genomic Valley Biotech in the lower half of its industry. The industry median PS Ratio is 9.38. Genomic Valley Biotech's value of 36.63 is 290.5% above this benchmark. Historically, Genomic Valley Biotech's own PS Ratio has ranged from 2.33 to 140.53 over the past decade. While the company's 10-year median is 16.03 vs. the industry median of 9.38, Genomic Valley Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.38, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomic Valley Biotech's current PS Ratio of 36.63 is 290.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Genomic Valley Biotech and its competitors. For the Biotechnology industry, the median PS Ratio is 9.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomic Valley Biotech's current PS Ratio is 36.63, which is 129% above median its own 10-year median of 16.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomic Valley Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genomic Valley Biotech (BOM:539206) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹12.84, compared to a current price of ₹30.40 — trading 136.8% above its estimated fair value. The current PS Ratio is 36.63, which is 129% above median its 10-year median of 16.03 and 290.5% above the Biotechnology industry median of 9.38. Genomic Valley Biotech's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Genomic Valley Biotech (BOM:539206), the current PS Ratio is 36.63 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomic Valley Biotech (BOM:539206) Overvalued in 2026?
Based on GuruFocus' analysis, Genomic Valley Biotech stock appears to be overvalued.
The current stock price of ₹30.40 is trading 136.8% above its estimated GF Value™ of ₹12.84.
GuruFocus considers Genomic Valley Biotech to be Significantly Overvalued.
Key valuation signals for BOM:539206:
PS Ratio: 36.63 (129% above median its 10-year median of 16.03)
GF Value™: ₹12.84 vs. price of ₹30.40 (136.8% above fair value)
Industry Position: 290.5% above the Biotechnology median (#705 of 933)
No single metric tells the full story. See the BOM:539206 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomic Valley Biotech Ltd is an India-based biotechnology company operating in the fields of genomics, molecular diagnostics, and AI-driven healthcare. The Company provides Next-Generation Sequencing (NGS) based diagnostic services, oncology diagnostics, personalized healthcare solutions, genetic disease risk assessment, community genomic screening, and research process outsourcing services. Its business is mainly segmented into diagnostic services and research services, with a focus on genomics, bioinformatics, and AI-enabled data analysis. The Company operates mainly in India, while also serving international researchers and collaborators.
59GF Score
Get the complete analysis for BOM:539206
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539206 has been successfully added to your 
